Cannabis Law Report

AUGUST 13, 2021

We’re thrilled to be pursuing SalA and progressing research, as we strive for new treatments.”. Importantly, Revixia’s product will be paired with a digital therapeutic being developed by atai company Introspect Digital Therapeutics, with the aim of streamlining preparation, integration, and continued patient engagement. “In

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Veriheal

NOVEMBER 17, 2020

Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. But this has failed in the past and could prevent measures from moving forward this time unless new research could be presented to sway the state medical board’s decision.

Conditions 98

Conditions Research and Development Pharmaceutical Clinical Trials 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.

Research and Development 97

Research and Development Clinical Trials Treatment Compliance 97

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Veriheal

SEPTEMBER 18, 2020

Research Team to Study the Impact of CBD on Spinal Injury Pain. Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronic pain. Dr. Carins is a postdoctoral researcher who completed her Ph.D.

Treatment 98

Treatment Chronic Pain Research and Development CBD 98

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. . – July 28, 2021) – PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 21, 2021

CBG or cannabigerol is obtained from immature cannabis plants since it is not present in fully developed plants. In most fully developed cannabis plants with considerable THC and CBD concentrations, CBG levels are relatively low. Research has proven that CBG has many therapeutic qualities. Huntington’s disease.

Conditions 52

Conditions Research and Development Clinical Trials Oil 52

Veriheal

AUGUST 28, 2023

This discovery adds to the ongoing research on the medical use of psychedelics in psychiatry. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Current approaches to treat this condition are helpful but do not always provide full relief.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Veriheal

FEBRUARY 9, 2023

Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Magic Mushrooms: The Ticket to a Stress-Free MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

SpeedWeed

AUGUST 16, 2021

Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of ??5-MeO-DMT From Psychedelic Toad Venom to Medical Research.

Research and Development 52

Research and Development Clinical Trials Treatment Conditions 52

Project CBD

OCTOBER 26, 2023

The vast majority of the existing research is on how specific cannabinoids kill cancer, but a growing body of work is revealing how the entourage of compounds found in whole-plant cannabis kills cancer. Without increased blood flow, the tumor does not have enough nutrition to sustain its development.

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

Cannabis Law Report

JULY 25, 2022

together with research collaborators at the University of Auckland , have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). — MindBio Therapeutics (@MindBioTherap) July 10, 2022.

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Medicinal Marijuana Association

AUGUST 27, 2019

Extensive research in the United States and England on cannabis in the 1930s came to a halt with the beginning of World War II and did not pick up again afterwards due to the various laws and regulations that classified the plant as a drug.Legal issuescontinued to inhibit serious study until half a century ago, when Prof.

Research and Development 66

Research and Development Clinical Trials Patients Epilepsy 66

LifeCannMD

FEBRUARY 27, 2024

Medical Marijuana exhibits neuroprotective properties, meaning it can protect nerve cells against damage, degeneration, or impairment of function in conditions like epilepsy, where excessive neuronal activity can lead to damage. Inflammation in the brain is thought to contribute to the development and persistence of seizures.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

Cannabis Law Report

AUGUST 22, 2021

Company has also initiated preclinical studies aimed at treating psychologic and neurologic conditions. PsyBio intends to continue utilizing its resources to rapidly develop and test new drug candidates within this and other psychedelic categories in anticipation of launching future clinical trials.

Clinical Trials 98

Clinical Trials Research and Development Treatment Conditions 98

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Preliminary Research on CBD Oil. Pharmacies, as more profitable companies, have the resources to research the other cannabinoids present in CBD oil. Chronic alcoholism is a serious health condition.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Preliminary Research on CBD Oil. Pharmacies, as more profitable companies, have the resources to research the other cannabinoids present in CBD oil. Chronic alcoholism is a serious health condition.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D. May 11, 2022 02:00 AM Eastern Daylight Time.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Cannabis Law Report

NOVEMBER 9, 2021

Pavel Otáhal, contributing author and Head of the Gene Immunotherapy Research Department at ÚHKT, stated, “Our study compares the manufacture of CAR19 T-cells via PCR-made transposon DNA (LinearDNA) with mRNA encoding of the transposase against a conventional plasmid approach. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

MMJ Recs

JULY 9, 2024

Living with chronic conditions such as Multiple Sclerosis (MS) is profoundly challenging and impacts various aspects of daily life. Additionally, no current treatments can reverse existing neurological damage, highlighting the need for ongoing research into more effective therapies and potential cures.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

NOVEMBER 19, 2021

“These patent filings are critical components of PsyBio’s corporate development strategy. “These patent filings are critical components of PsyBio’s corporate development strategy. PsyBio remains interested in developing the intellectual property landscape within the psycho-targeted development drug arena.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960).

Treatment 52

Treatment Research and Development CBD eCommerce 52

MMJ Recs

JULY 5, 2024

In states where it is legal, dispensaries report increasing sales of THC-infused products aimed at alleviating various health conditions. Understanding THC’s mechanisms and clinical implications is crucial as researchers continue to uncover its therapeutic potential and limitations in medical settings.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

The Cannigma

APRIL 12, 2023

What this means for CBN research These results are, in a word, impressive. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. A 2021 review examined all 99 of the existing human research studies on CBN and found just eight studies that met stringent criteria for reliable results.

Sleep 135

Sleep Data Tincture Research and Development 135